Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 8/20 | 0.33 |
| ▸ | CA1 | P00915 | 8/20 | 0.33 |
| ▸ | CA2 | P00918 | 8/20 | 0.33 |
| ▸ | CA4 | P22748 | 8/20 | 0.33 |
| ▸ | CA7 | P43166 | 8/20 | 0.33 |
| ▸ | CA9 | Q16790 | 8/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922495 | 0.88 | — | — | |
| SCHEMBL12161224 | 0.82 | FBP1 (0.42) | MAPTKDM4EALDH1A1POLB | |
| SCHEMBL9922480 | 0.79 | MAPT (0.34) | MAPTKDM4EALDH1A1CA12CA1 | |
| SCHEMBL12177641 | 0.79 | KCNH2 (0.35) | HRH3 | |
| SCHEMBL12177317 | 0.74 | POLB (0.35) | MAPTALDH1A1CA12CA1CA2 | |
| SCHEMBL14113573 | 0.74 | — | — | |
| SCHEMBL9922109 | 0.73 | P2RY12 (0.45) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL13638535 | 0.72 | MAPK14 (0.36) | MAPT | |
| SCHEMBL12177438 | 0.72 | KMT2A (0.36) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9922116 | 0.72 | FBP1 (0.45) | MAPTKDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | MAPT 4832/4885KDM4E 2312/4885ALDH1A1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.